Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

Biotechnology

Healthcare
$9.24 -3.20%

-$0.39 today

Market cap
$326.66M
Beta
0.89
P/E (TTM)
-7.5
EPS (TTM)
-$1.57
52W Low $3.69High $16.33

Volume 0.20M

Average 0.26M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$68.06M

FY 2025 · Annual

Net Income

-$59.98M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050M00
Cost of Revenue000258K0
Gross Profit0050M(258K)0
Gross Margin——100.0%——
Research & Development22.36M16.89M27.6M38.16M51.52M
Selling, General & Admin6.29M5.83M6.32M12.47M16.54M
Operating Expenses28.65M22.72M66.08M50.64M68.06M
Depreciation & Amortization325K329K195K258K323K
EBITDA(28.34M)(23.54M)23.57M(42M)(59.66M)
EBITDA Margin——47.1%——
Operating Income(28.65M)(22.72M)(16.08M)(50.89M)(68.06M)
Operating Margin——-32.2%——
Interest Income77K761K4.61M8.91M8.25M
Interest Expense332K388K208K00
Other Income / Expenses(354K)(1.53M)39.25M8.64M8.08M
Income Before Tax(29M)(24.25M)23.17M(42.26M)(59.98M)
Pre-Tax Margin——46.3%——
Income Tax Expense00450K00
Net Income(29M)(24.25M)22.72M(42.26M)(59.98M)
Net Margin——45.4%——
EPS (Basic)(1.15)(0.97)0.13(1.63)(2.17)
EPS (Diluted)(1.15)(0.97)0.13(1.63)(2.17)
Weighted Avg Shares25.13M25.13M25.13M25.85M27.7M
Weighted Avg Shares (Diluted)25.13M25.13M25.13M25.85M27.7M

CTNM Earnings Waterfall · TTM

NASDAQ:CTNM · Revenue to Net Income

Key Ratios

EPS$-1.95
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.6
P/S Ratio0.0

Analysis

$0 of revenue converted into -$58.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 5, 2026
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
SC 13GSC 13G filingOct 28, 2026

How much revenue does CTNM generate?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported $0.00 of revenue in fiscal 2025.

Is CTNM profitable?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported -$59.98M of net income.